Cure My Disease

Don't miss your cure!

 Log in / Sign up

First patients receive experimental drug in global cancer trial

NCT ID NCT05005403

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test the safety and behavior of a new drug called azirkitug. It will be given alone and in combination with two other cancer drugs to adults with advanced solid tumors, including lung and head and neck cancers, who have already tried standard treatments. The main goals are to find a safe dose and see how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital /ID# 250405

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Asan Medical Center /ID# 252289

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • CHA Bundang Medical Center /ID# 252291

    RECRUITING

    Seongnam, Gyeonggido, 13496, South Korea

  • Carolina BioOncology Institute /ID# 232597

    RECRUITING

    Huntersville, North Carolina, 28078, United States

    Contact Phone: •••-•••-••••

  • City of Hope National Medical Center /ID# 276272

    RECRUITING

    Duarte, California, 91010, United States

  • Community Health Network, Inc. /ID# 243011

    RECRUITING

    Indianapolis, Indiana, 46250-2042, United States

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593

    RECRUITING

    Fort Wayne, Indiana, 46804, United States

  • Hadassah Medical Center-Hebrew University /ID# 252287

    RECRUITING

    Jerusalem, 91120, Israel

  • Kansai Medical University Hospital /ID# 276805

    RECRUITING

    Hirakata-shi, Osaka, 573-1191, Japan

  • Kobe University Hospital /ID# 250409

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • NEXT Oncology /ID# 243007

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Austin /ID# 243005

    RECRUITING

    Austin, Texas, 78705-1171, United States

  • National Cancer Center /ID# 252290

    RECRUITING

    Goyang-si, Gyeonggido, 10408, South Korea

  • National Cancer Center Hospital /ID# 238372

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 238840

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 252262

    RECRUITING

    Tainan, 704, Taiwan

  • National Taiwan University Hospital /ID# 251894

    RECRUITING

    Taipei City, Taipei, 100, Taiwan

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Norton Cancer Institute /ID# 248903

    RECRUITING

    Louisville, Kentucky, 40241-2832, United States

  • Rabin Medical Center /ID# 250497

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus /ID# 238333

    RECRUITING

    Haifa, 3109601, Israel

  • START Midwest /ID# 248685

    RECRUITING

    Grand Rapids, Michigan, 49546-7062, United States

  • Shizuoka Cancer Center /ID# 250408

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • South Texas Accelerated Research Therapeutics (START) /ID# 276268

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Start Mountain Region /ID# 276270

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Taipei Medical University Hospital /ID# 252450

    RECRUITING

    Taipei, 11031, Taiwan

  • Taipei Medical University Shuang Ho Hospital /ID# 252449

    RECRUITING

    New Taipei City, 23561, Taiwan

  • The Catholic University of Korea, Seoul St. Marys Hospital /ID# 252867

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06591, South Korea

  • The Chaim Sheba Medical Center /ID# 238332

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The University of Texas MD Anderson Cancer Center /ID# 270059

    RECRUITING

    Houston, Texas, 77030, United States

  • Tri-Service General Hospital /ID# 252263

    RECRUITING

    Taipei, 11490, Taiwan

  • University of Illinois Hospital and Health Sciences System /ID# 251750

    RECRUITING

    Chicago, Illinois, 60607, United States

  • Virginia Cancer Specialists - Fairfax /ID# 232592

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Wakayama Medical University Hospital /ID# 276806

    RECRUITING

    Wakayama, Wakayama, 641-8510, Japan

  • Yonsei University Health System Severance Hospital /ID# 252288

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

GASTRIC/ESOPHAGEAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HIGH-GRADE SEROUS OVARIAN CANCER MICRO SATELLITE STABLE COLORECTAL CANCER NON SMALL CELL LUNG CANCER PANCREATIC CANCER TRIPLE NEGATIVE BREAST CANCER